Actively Recruiting
Local And Systemic Macrophage Activation in Coronary and Peripheral Artery Disease: the LAST-COP Study
Led by Maria Cecilia Hospital · Updated on 2026-05-14
60
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are investigating the role of macrophages in the instability of coronary artery lesions and how circulating monocytes relate to these macrophages. This study focuses on comparing macrophage presence and activation in both coronary and peripheral artery disease, aiming to understand their distribution in relation to monocyte subpopulations. The conditions studied include stable coronary artery disease, acute coronary syndromes, intermittent claudication, and critical limb ischemia. Participants will undergo Optical Coherence Tomography assessment, a diagnostic test that evaluates the number of infiltrating macrophages within atherosclerotic lesions. The study includes groups with different artery diseases such as stable coronary artery disease, acute coronary syndrome, intermittent claudication, and critical limb ischemia. This is a non-randomized interventional study without masking or placebo control. During the study, researchers will monitor the presence and activation of macrophages in coronary and peripheral lesions from enrollment until hospital discharge after angiography procedures. The main outcome measured is macrophage presence and activation in these lesions. Participants will be observed closely during this period to correlate these findings with circulating monocyte subpopulations. The total duration of participation spans from enrollment through the hospital stay following angiography.
CONDITIONS
Brief Title
Local And Systemic Macrophage Activation in Coronary and Peripheral Artery Disease
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Patients with chronic coronary artery disease
- Patients with no-ST elevation acute coronary syndrome
- Patients with chronic claudication classified as Rutherford II-III
- Patients with critical limb ischemia classified as Rutherford IV-V
- Adults aged 18 years or older
You will not qualify if you...
- Severe renal dysfunction
- Severe valve disease
- Advanced heart failure
- Advanced liver disease
- Chronic inflammatory or autoimmune disease
- Use of anti-inflammatory drugs
- Acute infection
- Recent surgical procedures
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - From enrollment to hospital discharge following peripheral angiography or coronary angiography
Participants undergo optical coherence tomography to assess macrophage presence and activation within coronary and peripheral atherosclerotic lesions.
1 to 2 visits depending on diagnostic procedures
Trial Site Locations
Total: 1 location
1
Maria Cecilia Hospital
Cotignola, Ravenna, Italy, 48033
Actively Recruiting
Research Team
R
Roberto Nerla, MD, PhD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
DIAGNOSTIC
Number of Arms
4
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here